close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

25.17 -1.26 (-4.78%)
Streaming Delayed Price Updated: 10:52 AM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 31,840,256
Open 26.44
Bid (Size) 25.16 (6,000)
Ask (Size) 25.17 (4,000)
Prev. Close 26.43
Today's Range 25.07 - 26.50
52wk Range 20.91 - 27.69
Shares Outstanding 5,606,688,356
Dividend Yield 6.83%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
These S&P500 stocks are gapping in today's session ↗
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the S&P500 gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Why Pfizer's 2026 Guidance Miss Is 'Not A Major Surprise' ↗
Pfizer issued a light outlook for 2026 on Tuesday, missing Wall Street's earnings forecast following a suite of acquisitions. 
Via Investor's Business Daily

Performance

YTD
-5.4%
-5.4%
1 Month
+0.3%
+0.3%
3 Month
+5.0%
+5.0%
6 Month
+3.1%
+3.1%
1 Year
-0.3%
-0.3%

More News

Read More
News headline image
Pfizer Sees Slower 2026 Growth Despite Pipeline Push, Cost Cuts ↗
Via Benzinga
News headline image
Pfizer Adds to Its Big Bet on Weight Loss Drugs ↗
Via MarketBeat
News headline image
Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance
From Pfizer Inc.
Via Business Wire
News headline image
Where Will Eli Lilly Be in 10 Years? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
These S&P500 stocks are the most active in today's session ↗
Via Chartmill
News headline image
Pfizer Faces Another Quiet Year As Patent Losses Cloud 2026 Outlook: Analyst ↗
Via Benzinga
Topics Intellectual Property
News headline image
Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Will Dogecoin Reach $1 By the End of the Year? ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Forget Teladoc and Buy This Healthcare Stock Instead ↗
Via The Motley Fool
News headline image
Rigani Press Announces Barnes & Noble Book Signing for Dr. S. Yin Ho's Groundbreaking Book
Via PRLog
Topics Artificial Intelligence
News headline image
Pfizer Declares First-Quarter 2026 Dividend
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026. ↗
Via The Motley Fool
News headline image
The Best Turnaround Stock to Invest $1,000 in Right Now ↗
Via The Motley Fool
News headline image
The Great Divergence: Investors Retreat from High-Flying Tech as Market Seeks New Equilibrium
Via MarketMinute
Topics Artificial Intelligence Economy Law Enforcement
News headline image
Great Rotation: Tech Exodus Fuels Dow's Record Run While Nasdaq Struggles
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
Value Stocks Stage a Comeback Bid Amidst Persistent Growth Dominance
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Moderna And Super Micro Top S&P 500 Short Interest List — Are They Ripe For A Squeeze? ↗
Via Stocktwits
Topics Artificial Intelligence Stocks
News headline image
Warning: This Skyrocketing Stock Has a Hidden Risk ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Pfizer's Tukysa Combo Shows Strong PFS Benefit In Metastatic Breast Cancer ↗
Via Benzinga
News headline image
Markets Brace for Anticipated Fed Rate Cut Amidst Shifting Economic Landscape
Via MarketMinute
Topics Artificial Intelligence Bonds Credit Cards
News headline image
TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer
From Pfizer Inc.
Via Business Wire
News headline image
Down 50%, Should You Buy the Dip on Pfizer? ↗
Via The Motley Fool
Topics Intellectual Property

Frequently Asked Questions

Is Pfizer publicly traded?
Yes, Pfizer is publicly traded.
What exchange does Pfizer trade on?
Pfizer trades on the New York Stock Exchange
What is the ticker symbol for Pfizer?
The ticker symbol for Pfizer is PFE on the New York Stock Exchange
What is the current price of Pfizer?
The current price of Pfizer is 25.17
When was Pfizer last traded?
The last trade of Pfizer was at 12/16/25 10:52 AM ET
What is the market capitalization of Pfizer?
The market capitalization of Pfizer is 141.10B
How many shares of Pfizer are outstanding?
Pfizer has 141B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today